EP3411013A1 - Emulsion comprising an nk-1 receptor antagonist - Google Patents

Emulsion comprising an nk-1 receptor antagonist

Info

Publication number
EP3411013A1
EP3411013A1 EP16708789.9A EP16708789A EP3411013A1 EP 3411013 A1 EP3411013 A1 EP 3411013A1 EP 16708789 A EP16708789 A EP 16708789A EP 3411013 A1 EP3411013 A1 EP 3411013A1
Authority
EP
European Patent Office
Prior art keywords
emulsion
oil
receptor antagonist
emulsifier
aqueous phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16708789.9A
Other languages
German (de)
English (en)
French (fr)
Inventor
Thomas B. Ottoboni
Han Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heron Therapeutics LLC
Original Assignee
Heron Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heron Therapeutics LLC filed Critical Heron Therapeutics LLC
Publication of EP3411013A1 publication Critical patent/EP3411013A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the disclosure relates generally to emulsion formulations and systems for the intravenous or parenteral administration of an NK-1 receptor antagonist for treatment of emesis.
  • the emulsion formulations are stable for prolonged periods of time. Also described are methods for preparing the stable NK-1 receptor antagonist emulsions and pharmaceutical formulations.
  • Emesis is a critical problem experienced as a result of anticancer cytotoxic therapy.
  • CINV chemotherapy -induced nausea and vomiting
  • Navari et al. (1999, N Engl J Med, 340: 190-195) showed that neurokinin-1 (NK-1) receptor antagonists improve CINV when used in combination with cisplatin-based chemotherapy.
  • NK-1 receptor antagonists block binding of substance P to the receptor, thereby preventing or limiting induction of vomiting pathways mediated by the NK-1 receptor (Aziz, 2012, Ann Palliat Med, 1 : 130-136).
  • NK-1 receptor antagonists currently approved and marketed include aprepitant and rolapitant HCl, which are both available in oral form.
  • oral dosage forms can create a problem for patients suffering from emesis, specifically, for example, on days two and three of chemotherapy. Accordingly, it is desirable to have injectable formulations to simplify treatment for these patients.
  • emulsions formulated for administering to a patient by injection are formulated to contain neurokinin-1 receptor antagonists which may be poorly soluble in aqueous solvents or unstable in aqueous-based liquid formulations.
  • Liquid formulations containing NK-1 receptor antagonists having poor solubility and/or poor gastrointestinal permeability characteristics can be very challenging to formulate for purposes of long-term storage and for administration.
  • One means of addressing this challenge is to prepare an emulsion which may both allow preparation of an injectable formulation as well as enhance bioavailability of the active agent once administered.
  • Intravenous emulsions should have a very small droplet size to circulate in the bloodstream without causing capillary blockage and embolization. These size limits are typified by USP33-NF28 General Chapter ⁇ 729> for Globule Size Distribution in Lipid Injectable Emulsions, hereinafter referred to as USP ⁇ 729>, which defines universal limits for (1) mean droplet size not exceeding 500 nm or 0.5 ⁇ and (2) the population of large-diameter fat globules, expressed as the volume-weighted percentage of fat greater than 5 ⁇ (PFAT5) not exceeding 0.05%, irrespective of the final lipid concentration.
  • Emulsion formulations must be physically stable.
  • Emulsion formulations must also be chemically stable.
  • the drug substance may degrade; for example, lipophilic drugs will partition into the oil phase, which will confer some degree of protection, but hydrolytic degradation may still occur at the oil-water interface.
  • Possible chemical degradation within parenteral fat emulsions includes oxidation of unsaturated fatty acid residues present in triglyceride and lecithin, and hydrolysis of phospholipids leading to the formation of free fatty acids (FFA) and lysophospholipids.
  • FFA free fatty acids
  • Such degradants lower pH, which may then promote further degradation.
  • pH should be controlled during manufacture and parenteral emulsion formulations may include a buffering agent to provide additional control. Any decrease in pH over the assigned shelf-life may be indicative of chemical degradation.
  • emulsion formulations were prepared and characterized to identify a formulation and process that will allow an NK-1 receptor antagonist compound to be incorporated into an emulsion for intravenous injection and remain stable during the shelf life of the formulation.
  • a pharmaceutical composition suitable for intravenous administration which comprises a stable emulsion comprising an oil phase, wherein the oil phase comprises a neurokinin 1 (NK-1) receptor antagonist, a surfactant and a co-surfactant; and an aqueous phase, wherein the aqueous phase comprises water, a tonicity agent, and a pH modifier.
  • NK-1 neurokinin 1
  • the NK-1 receptor antagonist is selected from the group consisting of aprepitant, rolapitant, netupitant, lanepitant, vestipitant, orvepitant maleate, casopitant, ezlopitant, serlopitant, befetupitant and maropitant, or a pharmaceutically acceptable salt thereof.
  • the NK-1 receptor antagonist is poorly soluble in water.
  • the NK-1 receptor antagonist is selected from the group consisting of rolapitant, netupitant, casopitant, ezlopitant, vestipitant, serlopitant, maropitant, and orvepitant. [0013] In some embodiments, the NK-1 receptor antagonist is not aprepitant.
  • the composition is an oil-in-water emulsion comprising an oil wherein the oil is selected from the group consisting of coconut oil, olive oil, soybean oil, safflower oil, triglycerides, octyl and decyl glycerate, ethyl oleate, glyceryl linoleate, ethyl linoleate, glyceryl oleate, cholesteryl oleate/linoleate or a mixture thereof.
  • the oil is hydrolyzed.
  • the oil is structurally modified.
  • the emulsifier comprises a phospholipid.
  • the emulsifier is selected from the group consisting of egg phospholipids, soy phospholipids, phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids, mixed chain phospholipids, lysophospholipids, hydrogenated phospholipids, partially hydrogenated phospholipids, and mixtures thereof.
  • the co-surfactant comprises an alcohol. In other embodiments, the co-surfactant is ethanol.
  • the pH modifier comprises an oleate or pharmaceutically acceptable salt thereof.
  • the oleate is sodium, potassium or ammonium oleate.
  • the pH modifier is sodium oleate or a pharmaceutically acceptable salt thereof.
  • the pH modifier comprises a buffer.
  • the buffer is selected from the group consisting of phosphate buffer, citrate buffer, Tris buffer, carbonate buffer, succinate buffer, maleate buffer and borate buffer.
  • the buffer is selected from the group, phosphate buffered saline (PBS), modified PBS (PBS-mod) and citrate buffer.
  • the pH modifier comprises an oleate and a buffer.
  • the oleate is sodium oleate and the buffer is Tris buffer.
  • the pH modifier is selected from the group consisting of sodium hydroxide, potassium hydroxide, magnesium hydroxide, sodium carbonate, Tris, sodium linoleate, sodium oleate, potassium oleate, ammonium oleate, potassium carbonate, potassium linoleate, and mixtures thereof.
  • the composition comprises about 5 wt/wt% (weight/weight %) to 15 wt/wt%, 5 wt/wt% to 10 wt/wt%, 7 wt/wt% to 10 wt/wt%, 8 wt/wt% to 9 wt/wt%, or 9 wt/wt% to 10 wt/wt% oil.
  • the composition comprises about 8 wt/wt5, 8.5 wt/wt%, 9 wt/wt%, 9.5 wt/wt%, 10 wt/wt%, or 10.5 wt/wt% oil.
  • the oil is soybean oil.
  • the composition comprises about 10 wt/wt% to 20 wt/wt%, 12 wt/wt% to 17 wt/wt%, 13 wt/wt% to 16 wt/wt%, 13 wt/wt% to 15 wt/wt%, 14 wt/wt% to 15 wt/wt%, or 13 wt wt% to 14 wt wt% emulsifier.
  • the composition comprises about 13 wt/wt%, 13.5 wt/wt%, 14 wt wt%, 14.5 wt/wt%, 15 wt/wt%, 16 wt/wt%, 17 wt wt%, 18 wt/wt%, 19 wt/wt% or 20 wt/wt% emulsifier.
  • the emulsifier is a lecithin.
  • the lecithin is an egg yolk lecithin.
  • the composition comprises about 0.05 wt/wt% to 1.5 wt/wt%, 0.1 wt/wt% to 1.0 wt/wt%, 0.2 wt wt% to 0.8 wt/wt%, 0.3 wt/wt% to 0.7 wt/wt%, 0.4 wt/wt% to 0.6 wt/wt%, 0.4 wt/wt% to 0.5 wt/wt% oleate or salt thereof.
  • the composition comprises about 0.05 wt/wt%, 0.1 wt/wt%, 0.2 wt/wt%, 0.3 wt/wt%, 0.4 wt/wt%, 0.45 wt/wt%, 0.5 wt/wt%, 0.6 wt/wt%, 0.7 wt/wt%, 0.8 wt/wt%, 0.9 wt/wt%, 1.0 wt/wt% or 1.5 wt/wt% oleate or salt thereof.
  • the oleate is sodium oleate.
  • the oleate or sodium oleate is the pH modifier.
  • the composition comprises about 20 wt/wt% to 50 wt/wt%, 30 wt/wt% to 50 wt/wt%, 35 wt/wt% to 45 wt/wt%, 30 wt/wt% to 45 wt/wt%, 37 wt/wt% to 42 wt/wt%, 38 wt/wt% to 40 wt/wt%, 30 wt wt%, 31 wt/wt%, 32 wt/wt%, 33 wt/wt%, 34 wt/wt%, 35 wt/wt%, 36 wt wt%, 37 wt/wt%, 38 wt/wt%, 39 wt/wt%, 40 wt/wt%, 41 wt/wt%, 42 wt/wt%, 43 wt/wt%, 44 wt/wt%
  • the composition comprises about 20 wt/wt% to 50 wt/wt%, 30 wt/wt% to 50 wt/wt%, 35 wt/wt% to 45 wt/wt%, 30 wt/wt% to 45 wt/wt%, 37 wt/wt% to 42 wt/wt%, 38 wt/wt% to 40 wt/wt%, 30 wt/wt%, 31 wt/wt%, 32 wt/wt%, 33 wt/wt%, 34 wt/wt%, 35 wt/wt%, 36 wt wt%, 37 wt/wt%, 38 wt/wt%, 39 wt wt%, 40 wt/wt%, 41 wt/wt%, 42 wt wt%, 43 wt/wt%, 44 wt/wt%
  • the composition comprises about 40 wt/wt% to 80 wt/wt%, 50 wt/wt% to 70 wt/wt%, 55 wt/wt% to 65 wt/wt%, 57 wt/wt% to 63 wt/wt%, 58 to 60 wt/wt%, 35 wt/wt% to 40 wt/wt%, 30 wt/wt% to 40 wt/wt%, 50 wt/wt%, 51 wt/wt%, 52 wt/wt%, 53 wt/wt%, 54 wt/wt%, 55 wt/wt%, 56 wt/wt%, 57 wt/wt%, 58 wt/wt%, 59 wt/wt%, 60 wt/wt%, 61 wt/wt%, 62 wt/wt%
  • the composition comprises about 40 wt/wt% to 80 wt/wt%, 50 wt/wt% to 70 wt/wt%, 55 wt/wt% to 65 wt/wt%, 57 wt/wt% to 63 wt/wt%, 58 to 60 wt/wt%, 35 wt/wt% to 40 wt/wt%, 30 wt/wt% to 40 wt/wt%, 50 wt/wt%, 51 wt/wt%, 52 wt/wt%, 53 wt/wt%, 54 wt/wt%, 55 wt/wt%, 56 wt/wt%, 57 wt/wt%, 58 wt/wt%, 59 wt/wt%, 60 wt/wt%, 61 wt/wt%, 62 wt/wt%
  • the ratio of oil to NK-1 receptor antagonist (wt%:wt%) in the composition ranges from about 5 : 1 to 20:1, 5:1 to 15:1, 5:1 to 10:1, 11:1 to 20:1, 11:1 to 15:1, 12:1 to 16:1, 12:1 to 14:1, 11:1 to 15:1, 12:1 to 14:1, 12.5:1 to 13.5:1, 13:1 to 14:1, or 12:1 to 15:1.
  • the ratio of oil to NK-1 receptor antagonist (wt%:wt%) in the composition is about 11:1 to 20:1, 11:1 to 15:1, 12:1 to 16:1, 12:1 to 14:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 11.5:1, 12:1, 12.5:1, 13:1, 13.5:1, 14:1, 14.5:1 or 15:1, 15.5:1, 16:1.
  • the ratio of emulsifier to NK-1 receptor antagonist (wt%:wt%) in the composition ranges from about 10:1 to 30:1, 10:1 to 20:1, 15:1 to 30:1, 20:1 to 25:1, 18:1 to 22:1, 19:1 to 20:1, or 10:1 to 30:1.
  • the ratio of emulsifier:NK-l receptor antagonist (wt%:wt%) in the composition is about 10:1, 11:1, 13:1, 14:1, 15:1, 18:1, 19:1, 20:1, 21:1,22:123:1, 24:1, 25:1, or 30:1.
  • the ratio of (emulsifier plus oil) to NK-1 receptor antagonist (wt%:wt%) in the composition ranges from about 20:1 to 40:1, 25:1 to 35:1, 30:1 to 35:1, or 32:1 to 34:1. In other embodiments, the ratio of (emulsifier plus oil) to NK-1 receptor antagonist is about 25:1, 26:1, 27:1, 28:1, 29:130:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1 or 40:1.
  • the ratio of emulsifier to oil (wt%:wt%) in the composition ranges from about 0.5:1, to 4:1, 1:1 to 2:1, 1.25:1 to 1.75:1, or 1.4:1 to 1.6:1.
  • the ratio of emulsifier to oil (wt%:wt%) in the composition is about 0.5:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, 2:1, 1.05:1, 1.15:1, 1.25:1, 1.35:1, 1.45:1, 1.55:1, 1.65:1, 1.75:1, 1.85:1, or 1.95:1.
  • a therapeutic dose of the pharmaceutical composition comprises about 1 to 4 g, 1.5 to 3 g, 1.8 to 2.8 g, 2.3 to 2.8 g, 1.8 to 2.3 g, 1 g, 1.1 g, 1.2 g, 1.3 g, 1.4 g, 1.5 g, 1.6 g, 1.7 g, 1.8 g.1.9 g, 2 g, 2.1 g, 2.2 g, 2.3 g, 2.4 g, 2.5 g, 2.6 g, 2.7 g, 2.8 g.2.9 g, 3 g, 3.1 g, 3.2 g, 3.3 g, 3.4 g, 3.5 g, 3.6 g, 3.7 g, 3.8 g.3.9 g, 4 g emulsifier.
  • the emulsifier is a lecithin.
  • the emulsifier is egg yolk lecithin.
  • a therapeutic dose of the pharmaceutical composition comprises about 0.5 to 3 g, 1 to 2.5 g, 1 to 2 g, 1 to 1.5 g, 1.5 g to 2 g, 0.5g 0.6 g, 0.7 g, 0.8 g, 0.9 g, 1 g, 1.1 g, 1.2 g, 1.3 g, 1.4 g, 1.5 g, 1.6 g, 1.7 g, 1.8 g.1.9 g, 2 g, 2.1 g, 2.2 g, 2.3 g, 2.4 g, 2.5 g oil.
  • the oil is soybean oil.
  • a therapeutic dose of the pharmaceutical composition comprises about 50 to 600 mg, 100 to 600 mg, 100 to 500 mg, 100 to 400 mg, 100 to 300 mg, 100 to 200 mg, 200 to 400 mg, 50 to 250 mg, 75 to 200 mg, 100 to 150 mg, 100 mg, 1 10 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, or 600 mg of the NK-1 receptor antagonist.
  • the composition comprises about 0 wt/wt% to 10 wt/wt%, 1 wt/wt% to 9 wt/wt%, 2 wt/wt% to 6 wt/wt%, 2 wt/wt% to 4 wt/wt% or 2 wt/wt% to 3 wt/wt% co- surfactant.
  • the composition comprises less than 10 wt wt%, less than 9 wt/wt%, less than 8 wt/wt%, less than 7, less than 6 wt/wt%, less than 5 wt/wt%, less than 4 wt/wt%, less than 3 wt/wt%, less than 2 wt/wt% or less than 1 wt wt% co-surfactant.
  • the composition comprises about 0 wt/wt% to 10 wt/wt%, 1 wt/wt% to 9 wt/wt%, or 2 wt/wt% to 6 wt/wt% ethanol. In other embodiments, the composition comprises less than 10 wt/wt%, less than 9 wt/wt%, less than 8 wt/wt%, less than 7, less than 6 wt/wt%, less than 5 wt/wt%, less than 4 wt/wt%, less than 3 wt/wt%, less than 2 wt/wt% or less than 1 wt/wt% ethanol.
  • the aqueous phase of the emulsion comprises a tonicity agent, a pH modifier, and water.
  • the aqueous phase of the emulsion comprises an osmotic agent, a pH modifier, and water.
  • the aqueous phase of the emulsion comprises a tonicity agent, an osmotic agent, a pH modifier, and water.
  • the aqueous phase further comprises a buffer.
  • the aqueous phase comprises a buffer but does not comprise a pH modifier which is different from the buffer.
  • the buffer functions as both a pH modifier agent and a buffer.
  • the composition when the aqueous phase comprises a buffer, the composition contains no tonicity agent.
  • the buffer is selected from the group consisting of phosphate buffer, citrate buffer, Tris buffer, carbonate buffer, succinate buffer, maleate buffer and borate buffer. In other embodiments, the buffer is selected from the group, phosphate buffered saline (PBS), modified PBS (PBS-mod) and citrate buffer.
  • PBS phosphate buffered saline
  • PBS-mod modified PBS
  • the aqueous phase comprises a buffer, that when mixed with the oil phase will provide a substantially isotonic oil in water emulsion.
  • the osmotic agent is selected from the group consisting of glycerol, sorbitol, xylitol, mannitol, glucose, trehalose, maltose, sucrose, raffinose, lactose, dextran, polyethylene glycol, or propylene glycol.
  • the osmotic agent is an inorganic salt such as sodium chloride and mixtures thereof.
  • the composition has a pH of about 6 to 9, 7 to 9, 7.5 to 9, 7.5 to 8.5, 8 to 9, 6 to 8, 7 to 8, or 6, 7, 8 or 9.
  • the composition comprises about 0 wt/wt% to 25 wt/wt%, 2 wt/wt% to 20 wt/wt%, 3 wt wt% to 15 wt/wt%, or 3 wt/wt% to 8 wt/wt% tonicity agent.
  • the composition comprises about 1 wt/wt%, 2 wt/wt%, 3 wt/wt%, 4 wt/wt%, 5 wt/wt%, 6 wt/wt%, 7 wt/wt%, 8 wt/wt%, 9 wt/wt%, or 10 wt/wt%, 11 wt/wt%, 12 wt/wt%, 13 wt/wt%, 14 wt/wt%, 15 wt/wt%, 16 wt/wt%, 17 wt wt%, 18 wt/wt%, 19 wt/wt%, or 20 wt/wt%, 21 wt/wt%, 22 wt/wt%, 23 wt/wt%, 24 wt/wt%, 25 wt/wt% tonicity agent.
  • the composition comprises no tonicity agent.
  • the composition comprises about 0 wt/wt% to 25 wt/wt%, 2 wt/wt% to 20 wt/wt%, 3 wt/wt% to 15 wt/wt%, or 3 wt/wt% to 8 wt/wt% osmotic agent.
  • the composition comprises about 1 wt/wt%, 2 wt/wt%, 3 wt/wt%, 4 wt/wt%, 5 wt/wt%, 6 wt/wt%, 7 wt/wt%, 8 wt/wt%, 9 wt/wt%, or 10 wt/wt%, 11 wt/wt%, 12 wt/wt%, 13 wt/wt%, 14 wt/wt%, 15 wt/wt%, 16 wt/wt%, 17 wt wt%, 18 wt/wt%, 19 wt/wt%, or 20 wt/wt%, 21 wt/wt%, 22 wt/wt%, 23 wt/wt%, 24 wt/wt%, 25 wt/wt% osmotic agent. In still other embodiments, the composition comprises no os
  • the aqueous phase comprises a dose of dexamethasone sodium phosphate in a therapeutic dose of the pharmaceutical composition.
  • the dose of dexamethasone sodium phosphate ranges from about 0.5 mg to 30 mg, 0.5 mg to 25 mg, 1 mg to 20 mg, 10 mg to 20 mg, or 3 mg to 16 mg.
  • the dose of dexamethasone sodium phosphate is about 9 mg or 16 mg in a therapeutic dose of the pharmaceutical composition.
  • the therapeutic dose of the pharmaceutical composition comprises about 50 to 600 mg, 100 to 600 mg, 100 to 500 mg, 100 to 400 mg, 100 to 300 mg, 100 to 200 mg, 200 to 400 mg, 50 to 250 mg, 75 to 200 mg, 100 to 150 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, or 600 mg of the NK-1 receptor antagonist.
  • the oil phase comprises a dose of dexamethasone in a therapeutic dose of the pharmaceutical composition.
  • the dose of dexamethasone ranges from about 0.5 mg to 30 mg, 0.5 mg to 20 mg, 1 mg to 18 mg, 10 mg to 20 mg, or 3 mg to 16 mg. In other embodiments, the dose of dexamethasone is about 8 mg or 12 mg in a therapeutic dose of the pharmaceutical composition.
  • the therapeutic dose of the pharmaceutical composition comprises about 50 to 600 mg, 100 to 600 mg, 100 to 500 mg, 100 to 400 mg, 100 to 300 mg, 100 to 200 mg, 200 to 400 mg, 50 to 250 mg, 75 to 200 mg, 100 to 150 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, or 600 mg of the NK-1 receptor antagonist.
  • the emulsion comprises about 0.002 wt/wt% to 0.2 wt/wt%, 0.003 wt/wt% to 0.16 wt/wt%, 0.02 wt/wt% to 0.1 wt/wt% dexamethasone sodium phosphate.
  • the composition is a stable system maintaining an intensity- weighted mean particle size as determined by dynamic light scattering (DLS) of about 50 nm to 1000 nm, 50 to 500 nm, 50 nm to 400 nm, 50 nm to 300 nm, 50 nm to 200 nm or 50 nm to 100 nm.
  • the average droplet size is maintained below 500 nm for a period of at least 1 month, 3 months, 6 months, 9 months, 12 months, 2 years or 3 years at room temperature.
  • the average droplet size is maintained below 500 nm for a period of at least 1 month, 3 months, 6 months, 9 months, 12 months, 2 years or 3 years at 5 °C.
  • a method for preparing an emulsion comprising an NK-1 receptor antagonist compound and suitable for parenteral administration is provided.
  • the administration is intravenous administration.
  • the method comprises: a) preparing an oil phase by dissolving the antagonist compound and an emulsifier in ethanol, then adding in oil to generate an oil-based mixture; b) preparing an aqueous phase by mixing water, optionally with a tonicity agent, optionally with an osmotic agent and optionally with a pH modifier and optionally with a buffer to generate an aqueous mixture; c) combining the oil-based mixture and the aqueous mixture and subjecting this to high speed homogenization to generate a crude emulsion; and d) subjecting the crude emulsion to high pressure homogenization to generate a fine emulsion.
  • preparing the oil phase further comprises dissolving dexamethasone with the antagonist compound and the emulsifier in the ethanol.
  • the method comprises: a) combining a NK-1 receptor antagonist, an emulsifier, and an alcohol with an oil to generate an oil phase; (b) combining water, a tonicity agent, a pH modifier, and optionally a buffer to generate an aqueous phase; (c) homogenizing the oil phase with the aqueous phase to generate the pharmaceutical emulsion; and (d) sterilizing the pharmaceutical emulsion.
  • the homogenizing comprises high speed homogenization.
  • the method comprises: a) preparing an oil phase by dissolving the antagonist compound and an emulsifier in ethanol and oil to generate an oil-based mixture; b) preparing an aqueous phase by mixing water, optionally with a tonicity agent, optionally with an osmotic agent and optionally with a pH modifier and optionally with a buffer to generate an aqueous mixture; c) combining the oil-based mixture and the aqueous mixture and subjecting this to homogenization to generate a crude emulsion; and d) subjecting the crude emulsion to homogenization to generate a fine emulsion.
  • the subjecting the homogenization to generate a crude emulsion is high-speed homogenization.
  • the homogenization to generate a fine emulsion is a high pressure homogenization.
  • preparing the oil phase further comprises dissolving dexamethasone with the antagonist compound and the emulsifier in the ethanol and oil.
  • preparing the aqueous phase further comprises mixing dexamethasone with the water, tonicity agent, pH modifier, and a buffer.
  • the dexamethasone is a salt of dexamethasone.
  • the dexamethasone is dexamethasone sodium phosphate.
  • the method further comprises sterilizing the fine emulsion to generate the final emulsion, wherein the final emulsion is suitable for injection into a subject.
  • the dissolution in ethanol is performed at a temperature of about 25 °C to 80 °C, 40 °C to 75 °C, 60 °C to 70 °C, or at about 25 °C, 35 °C, 45 °C, 60 °C, 65 °C, 70 °C or 75 °C.
  • the high-speed homogenization is performed at a speed of about 2,000 rpm (revolutions per minute) to 25,000 rpm. In other embodiments, the high-speed homogenization is performed at a speed of about 20,000 rpm. In still other embodiments, the highspeed homogenization is performed at a speed of about 3600 rpm.
  • the high-speed homogenization is performed for a time period of about 0.5 min to 1 hour, 1 min to 45 min, or 1 min to 30 min. In other embodiments, the high-speed homogenization is performed for a time period of about 20 to 40 min or for about 30 min.
  • the high-speed homogenization is performed at about 10 °C to about 60 °C, 20 °C to about 60 °C, about 30 °C to about 50 °C, or about 35 °C to about 45 °C. In another embodiment, the high-speed homogenization is performed at about 25 °C, 30 °C, 35 °C, 40 °C, 45 °C or 50 °C.
  • the high-pressure homogenization is performed at a pressure of about 10,000 psi (pounds per square inch) to 30,000 psi. In other embodiments, the high-pressure homogenization is performed at a pressure of about 20,000 psi.
  • the high-pressure homogenization is performed with cooling.
  • the high-pressure homogenization is performed with cooling which is sufficient to bring the temperature of the emulsion at the outlet of the process to about 0 °C to about 60 °C, about 10 °C to about 40 °C, about 20 °C to about 30 °C, or to about 20 °C, 25 °C or 30 °C within the time period.
  • the sterilizing the fine emulsion comprises filtering the fine emulsion through a nylon filter.
  • the nylon filter is a Posidyne® filter.
  • the filter has a pore size of about 0.2 ⁇ (micrometers).
  • the compositions are for use in a method for the treatment of emesis induced by a chemotherapeutic agent, by radiation-induced nausea and vomiting, and/or by post-operative induced nausea and vomiting in a subject.
  • the treatment comprises administering to the subject a composition comprising an NK-1 receptor antagonist as described herein.
  • the compositions are for use in preventing or treating acute and delayed nausea and vomiting.
  • FIGS. 1A-1D provides microscope images of samples from Examples 1, 2, 3 and 6 after a freeze-thaw cycle.
  • FIG. 1A Example 1
  • FIG. IB Example 2
  • FIG. 1C Example 3
  • FIG. ID Example 6
  • FIG. 2 shows plasma levels of aprepitant after injection of a fosaprepitant solution ( ⁇ ) or an aprepitant emulsion prepared as described herein (A).
  • FIG. 3 shows plasma levels of aprepitant after injection of a solution of fosaprepitant (A) or after injection of an emulsion containing aprepitant and dexamethasone prepared as described herein ( ⁇ ).
  • FIG. 4 shows plasma levels of dexamethasone after injection of a solution of dexamethasone sodium phosphate ( ⁇ ) or after injection of an emulsion containing aprepitant and dexamethasone prepared as described herein (A).
  • emulsion or "emulsion formulation” means a colloidal dispersion of two immiscible liquids in the form of droplets, whose diameter, in general, is between 10 nanometers and 100 microns.
  • An emulsion is denoted by the symbol OAV (oil-in-water) if the continuous phase is an aqueous solution and by W/O (water-in-oil) if the continuous phase is an oil.
  • OAV/O oil-in-water-oil
  • OAV/O oil-in-water-oil
  • “Physically stable" emulsions will meet the criteria under USP ⁇ 729>, which defines universal limits for (1) mean droplet size not exceeding 500 nm or 0.5 ⁇ and (2) the population of large-diameter fat globules, expressed as the volume-weighted percentage of fat greater than 5 ⁇ (PFAT5) not exceeding 0.05%, at 5 °C or room temperature for a designated storage time period.
  • physically stable emulsions will have no visible NK-1 receptor antagonist crystals upon storage at 5 °C or room temperature for a designated time period. Crystals are considered visible when viewed at magnification of 4X to 10X.
  • An emulsion is physically stable if it meets the criteria under USP ⁇ 729> and NK-1 receptor antagonist crystals are not visible upon storage at 5 °C or room temperature for a time period equal to or at least 1 week, 2 weeks, 4 weeks, 1 month, 2 months, 6 months, 1 year or 2 years.
  • “Chemically stable" emulsions of the disclosure are ones in which the concentration of the active component (i.e., the drug being delivered) does not change by more than about 20% under appropriate storage conditions for at least 1 month.
  • the concentration the NK-1 receptor antagonist in an emulsion of the present disclosure does not change by more than about 5%, 10%, 15% or 20% under appropriate storage conditions for at least 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, or 24 months.
  • the stable emulsion compositions of the disclosure are stable over a wide range of temperatures, e.g., -20 °C to 40 °C.
  • the compositions of the disclosure may be stored at about 5 °C to about 25 °C.
  • Oil phase in a water-in-oil emulsion refers to all components in the formulation that individually exceed their solubility limit in the water phase; these are materials that generally have solubilities of less than 1 % in distilled water, however, water phase components such as salts may decrease the solubility of certain oils resulting in their partitioning into the oil phase.
  • the oil phase refers to the non-aqueous portion of a water-in-oil emulsion.
  • Aqueous phase or “water phase” in a water-in-oil emulsion refers to the water present and any components that are water soluble, i.e., have not exceeded their solubility limit in water.
  • “Aqueous phase” includes a water-containing liquid which can contain pharmaceutically acceptable additives such as acidifying, alkalizing, buffering, chelating, complexing and solubilizing agents, antioxidants and antimicrobial preservatives, humectants, suspending and/or viscosity modifying agents, tonicity and wetting or other biocompatible materials.
  • the aqueous phase refers to the non-oil portion of a water-in-oil emulsion.
  • Emulsifier refers to a compound that deters the separation of the injectable emulsion into individual oil and aqueous phases.
  • Emulsifiers useful in the present disclosure generally are (1) compatible with the other ingredients of the stable emulsions of the present disclosure, (2) do not interfere with the stability or efficacy of the drugs contained in the emulsions, (3) are stable and do not deteriorate in the preparation, and (4) are non-toxic.
  • Suitable emulsifiers include, but are not limited to, propylene glycol mono- and di-fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene fatty acid esters, polyoxyethylene-polyoxypropylene co-polymers and block co-polymers, salts of fatty alcohol sulphates, sorbitan fatty acid esters, esters of polyethylene-glycol glycerol ethers, oil and wax based emulsifiers, glycerol monostearate, glycerine sorbitan fatty acid esters and phospholipids.
  • a "phospholipid” refers to a triester of glycerol in which the secondary alcohol and one of the primary alcohols has been esterified with fatty acids and the other primary alcohol has been esterified with a phosphate group.
  • Exemplary phospholipids useful in the present invention include, but are not limited to, phosphatidyl chlorine, lecithin (a mixture of choline ester of phosphorylated diacylglyceride), phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid with about 4 to about 22 carbon atoms, and more generally from about 10 to about 18 carbon atoms and varying degrees of saturation.
  • the phospholipids can have any combination of fatty acid as its fatty acyl side chain, for example, the phospholipids can have a saturated fatty acid such as a decanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, icosanoic acid, (a C20 saturated fatty acid); sodium behenic acid, or an unsaturated fatty acid such as myristoleic acid, palmitoleic acid, oleic acid, sodium linoleic acid, alpha linolenic acid, sodium arachidonic acid, eicosapentanoic acid, and the like.
  • the two fatty acyl residues on the phospholipids may be the same or they may be different fatty acids.
  • the phospholipid component of the drug delivery composition can be either a single phospholipid or a mixture of several phospholipids. The phospholipids should be acceptable for the chosen route of administration.
  • the phospholipids used as emulsifiers in the present invention are naturally occurring phospholipids from a natural origin.
  • naturally occurring lecithin is a mixture of the diglycerides of stearic, palmitic, and oleic acids, linked to the choline ester of phosphoric acid, commonly called phosphatidylcholine, and can be obtained from a variety of sources such as eggs and soya beans.
  • Soy lecithin and egg lecithin (including hydrogenated versions of these compounds) have been characterized in various compositions and are generally recognized to be safe, have combined emulsification and solubilization properties, and tend to be broken down into innocuous substances more rapidly than most synthetic surfactants.
  • lecithin includes a complex mixture of acetone-insoluble phosphatides, of which phosphatidylcholine is a significant component.
  • lecithin is also used as a synonym for phosphatidylcholine.
  • Useful lecithins include, but are not limited to, egg yolk-, egg-, soybean-, and corn-derived lecithin.
  • the emulsifier is lecithin, such as egg yolk-derived lecithin.
  • egg lecithin and egg yolk derived lecithin are used interchangeably throughout.
  • the compositions described herein preferably comprise lecithin as an emulsifier.
  • the amount of phospholipids, by weight, in the emulsions of the present disclosure may be within a range of about 10 wt/wt% to about 20 wt/wt%, 11 wt/wt% to 19 wt/wt%, 11 wt/wt% to 15 wt/wt%, 12 wt/wt% to 13 wt/wt%, 13 wt wt% to 14 wt/wt%, 13 wt/wt% to 20 wt/wt%, or 12 wt/wt% to 18 wt/wt%.
  • the phospholipids in the emulsions are at a concentration, by weight, about 11 wt/wt%, 12 wt/wt%, 12.5 wt/wt%, 13 wt/wt%, 13.5 wt/wt%, 14 wt/wt%, 14.5 wt/wt%, or 15 wt/wt%.
  • Oil refers to an organic liquid of mineral, vegetable, animal, essential or synthetic origin, including, for example, aliphatic or wax-based hydrocarbons, aromatic hydrocarbons or mixed aliphatic and aromatic hydrocarbons.
  • buffer or "buffered” as used herein means a solution containing both a weak acid and its conjugate base, whose pH changes only slightly upon addition of acid or base.
  • buffering agent means a species whose inclusion in a solution provides a buffered solution. Buffers are well-known in the art and readily available.
  • Buffers for use according to the methods and compositions described herein include but are not limited to phosphate, citrate, Tris, carbonate, succinate, maleate, borate, MES, Bis-Tris, ADA, aces,PIPES, MOPSO, Bis-Tri Propane, BES, MOPS, TES, HEPES, DIPSO, MOBS, TAPSO, Trizma, HEPPSO, POPSO, TEA, EPPS, Tricine, Gly-Gly, Bicine, GEPBS, TAPS, AMPD, TABS, AMPSO, CHES, CAPSO, AMP, CAPS, and CABS.
  • the term "therapeutic agent” describes any natural or synthetic compound which has a biological activity.
  • a "therapeutically effective amount” means the amount that, when administered to an animal or subject for treating or preventing a disorder, condition, or disease, is sufficient to effect treatment for that disorder, condition, or disease.
  • the term "emesis” includes nausea and vomiting.
  • the present disclosure is directed to stable pharmaceutical compositions including an NK-1 receptor antagonist, a surfactant or mixtures of surfactants, a co-surfactant, an oil, with an aqueous phase.
  • the composition can be an injectable emulsion and is in the form of an oil-in- water emulsion which remains stable over an extended period of time and which is suitable for dilution and intravenous administration.
  • the NK-1 receptor antagonist compound is present in the oil phase with an emulsifier, a co-surfactant and an oil.
  • the oil phase is then combined with an aqueous phase comprising water and a tonicity agent as described below to generate the stable emulsion.
  • the oil phase Prior to combining the oil phase with the aqueous phase, the oil phase will have an oil: antagonist compound ratio of about 11 : 1 to 30: 1, 11 : 1 to 15: 1, or about 13: 11.
  • an oil:aprepitant ratio of about 13: 1 was surprisingly found to produce, when mixed with the water phase, an emulsion which is more stable as compared to an emulsion in which the oil phase contains an oil: aprepitant ratio of less than about 12: 1 or 11 : 1, and/or greater than about 15: 1, 20: 1, or 30: 1.
  • the stable emulsion comprising an NK-1 receptor antagonist and to be administered to the subject can have an oil: antagonist compound ratio of about 11 : 1 to 30:, 11 : 1 to 15: 1, or about 13: 11.
  • the oil: antagonist compound ratio is about 5: 1 to 20: 1, 5: 1 to 15: 1 or 5: 1 to 10: 1.
  • the present compositions also possess favorable stability properties when the amount of emulsifier in the oil phase is greater than the amount of oil.
  • the oil phase contains an emulsifier: oil ratio of about 5: 1 to 1 : 1, 3: 1 to 1 : 1 or a ratio of about 1.5: 1.
  • Such ratios of emulsifier: oil have surprisingly been found to impart greater stability on a final emulsion which is suitable for injection into a patient.
  • an aprepitant emulsion having a phospholipid: oil ratio within the oil phase of about 1.5: 1 was found to have greater stability than a similar aprepitant emulsion, wherein the oil phase comprises a phospholipid: oil ratio of about 0.01 : 1, 0.1 : 1, 0.5: 1 or 0.9: 1.
  • Suitable NK-1 receptor antagonists for use in the presently described pharmaceutical emulsions include RP 67580 ((3aR,7aR)-Octahydro-2-[l-imino-2-(2-methoxyphenyl)ethyl]-7,7- diphenyl-4H-isoindol)), WIN 51078 (17- -Hydroxy-17-a-ethynyl-5-a-androstano[3,2- b]pyrimido[l,2-a]benzimidazole), 1-733,060, (((2S,3S)-3-[[3,5-bis(Trifluoromethyl) phenyl] methoxy]-2-phenylpiperi dine hydrochloride), 1-703,606 (cis-2-(Diphenylmethel)-N- ([2- iodophenyl]methyl)-l-azabicyclo(2.2.2)octan-3-amine)
  • the oil (hydrophobic) phase comprises an oil.
  • Triglycerides are exemplary oils for use in the compositions described herein.
  • the oil is or comprises a vegetable oil.
  • "Vegetable oil” refers to oil derived from plant seeds or nuts. Vegetable oils are typically "long- chain triglycerides” (LCTs), formed when three fatty acids (usually 14 to 22 carbons in length, with unsaturated bonds in varying numbers and locations, depending on the source of the oil) form ester bonds with the three hydroxyl groups on glycerol.
  • LCTs long- chain triglycerides
  • vegetable oils of highly purified grade also called “super refined” are used to ensure safety and stability of the oil-in-water emulsions.
  • hydrogenated vegetable oils which are produced by controlled hydrogenation of the vegetable oil
  • exemplary vegetable oils include but are not limited to almond oil, babassu oil, black currant seed oil, borage oil, canola oil, castor oil, coconut oil, corn oil, cottonseed oil, olive oil, peanut oil, palm oil, palm kernel oil, rapeseed oil, safflower oil, soybean oil, sunflower oil and sesame oil. Hydrogenated and/or or partially hydrogenated forms of these oils may also be used.
  • the oil is or comprises safflower oil, sesame oil, com oil, olive oil and/or soybean oil.
  • the oil is or comprises safflower oil, and/or soybean oil.
  • the oil is present in the emulsion at about 9 wt/wt%, though this may vary between about 5 wt/wt% to 12 wt/wt% or 9 wt/wt% to 10 wt/wt%.
  • the NK-1 receptor antagonist is first mixed with an emulsifier such as a phospholipid emulsifier.
  • an emulsifier such as a phospholipid emulsifier.
  • Examples 1-6 and 11-19 are examples in which NK-1 receptor antagonist emulsions made using an egg lecithin.
  • a phoshoplipid emulsifier is added to a concentration of greater than 10 wt/wt%, 11 wt/wt%, 12 wt/wt% or 13 wt/wt% of the emulsion but less than 15 wt/wt%, 17 wt/wt% or 20 wt/wt% of the emulsion.
  • the mixture of antagonist and emulsifier is dissolved in a co-surfactant such as a short chain alcohol (1 to 6 carbons).
  • a co-surfactant such as a short chain alcohol (1 to 6 carbons). Examples 1-6 and 11-19 below are some examples in which the co- surfactant is ethanol.
  • the mixture is mixed at an elevated temperature, such as at about 60 °C or 70 °C or at an elevated temperature within the range of about 50 °C or 70 °C, until the NK-1 receptor antagonist and emulsifier are dissolved.
  • This mixture is then combined with the oil, such as soybean oil, by mixing again at an elevated temperature such as at about 60 °C to produce the oil phase containing the NK-1 receptor antagonist.
  • Excess co-surfactant can be removed by standard evaporation methods including heating, or pressure reduction, or a combination thereof such employed in a rotary evaporator. In this process, about 10% to 100%, 20% to 95%, 80% to 100%, 90% to 100%, or 95% to 100% of the ethanol evaporates depending on preparation scale, any pressure reduction, and heating time.
  • the NK-1 receptor antagonist and the emulsifier are dissolved in a co-surfactant and an oil.
  • a co-surfactant is ethanol and the oil is soybean oil, however, the methods can be used with any one or more of the co-surfactants and oils described herein.
  • the mixture is mixed at an elevated temperature, such as at about 60 °C or 70 °C or at an elevated temperature within the range of about 50 °C or 70 °C, at least until the NK-1 receptor antagonist and emulsifier are dissolved to produce the oil phase containing the NK-1 receptor antagonist.
  • the mixture of NK-1 receptor antagonist, emulsifier, co-surfactant and oil are mixed at the elevated temperature for about 15 min to 120 min, about 15 min to 45 min, about 30 min to 90 min, or for about 15 min, 30 min or 50 min.
  • Excess co-surfactant can be removed by standard evaporation methods including heating, or pressure reduction, or a combination thereof in a rotary evaporator. During this process, about 10% to 100%, 20% to 95%, 80% to 100%, 90% to 100%, or 95% to 100% of the ethanol evaporates depending on preparation scale, any pressure reduction, and heating time.
  • dexamethasone is added to the oil phase comprising the NK-1 receptor antagonist, emulsifier and oil to generate an oil phase comprising both the NK-1 receptor antagonist and dexamethasone prior to mixing with the aqueous phase to generate the pharmaceutical emulsion for injection.
  • Dexamethasone is added to the oil phase to provide a dose of about 12 mg dexamethasone.
  • the aqueous phase of the NK-1 receptor antagonist emulsion can be a mixture of water and a tonicity agent, including those such as but not limited to sucrose, mannitol, glycerin or dextrose or a mixture thereof.
  • a pH-modifying agent pH modifier
  • Sodium oleate is used in Examples 1-3, 5, 6, and 11-15, and 17-19 below to adjust the pH of the emulsion to about 6 to 9, depending on the desired emulsion formulation.
  • the pH modifier can be other oleic acids or salts thereof including but not limited to sodium oleate, potassium oleate and ammonium oleate.
  • the oleic acid can comprise about 0.1 wt/wt% to 1.0 wt/wt% or about 0.4 wt/wt% or 0.5 wt/wt% of the stable injectable emulsions as provided herein.
  • the aqueous phase is produced by mixing water with the tonicity agent and pH modifier (e.g., sodium oleate). Additional pH modifiers that may be used include but are not limited to sodium hydroxide, potassium hydroxide, magnesium hydroxide, Tris, sodium carbonate and sodium linoleate.
  • the pH modifier comprises more than one pH modifier.
  • the aqueous phase may comprise both an oleate and a buffer such as a Tris buffer.
  • the pH modifier used is effective for adjusting the pH of the emulsion to a preferred pH of about 6 to 9, 7 to 8, or about 6, 7, 8 or 9.
  • the aqueous phase can readily form by mixing at room temperature.
  • the aqueous phase of the emulsion may further contain a buffering agent to promote stability of the emulsion formulation.
  • the drug substance may degrade; for example, lipophilic drugs will partition into the oil phase, which will confer some degree of protection, but hydrolytic degradation may still occur at the oil-water interface.
  • Possible chemical degradation within parenteral fat emulsions includes oxidation of unsaturated fatty acid residues present in triglyceride and lecithin, and hydrolysis of phospholipids leading to the formation of free fatty acids (FFA) and lysophospholipids.
  • FFA free fatty acids
  • pH should be controlled during manufacture and emulsion formulations may include a buffering agent to provide additional control.
  • Suitable buffers are well known to the person skilled in the art and include but are not limited to a phosphate buffer, citrate buffer, Tris buffer, carbonate buffer, succinate buffer, maleate buffer or borate buffer.
  • Tris buffer is used in Examples 11 and 19 below to adjust the pH of the emulsion to about 8 to 9.
  • a buffer such as Tris buffer can be used in addition to another pH modifier (e.g., oleate or sodium oleate) to adjust or modify the pH of the emulsion.
  • the buffer is selected from the group, phosphate buffered saline (PBS), modified PBS (PBS-mod) and citrate buffer.
  • the aqueous phase comprises a buffer, that when mixed with the oil phase will provide a substantially isotonic oil in water emulsion.
  • Buffering agents useful for the presently described compositions include, but are not limited to, a phosphate buffer, citrate buffer, Tris buffer, carbonate buffer, succinate buffer, maleate buffer or borate buffer.
  • the buffer is selected from the group, phosphate buffered saline (PBS), modified PBS (PBS-mod) and citrate buffer.
  • the aqueous phase comprises a buffer, that when mixed with the oil phase will provide a substantially isotonic oil in water emulsion.
  • the aqueous phase when the aqueous phase contains a buffering agent, the aqueous phase does not include a tonicity agent.
  • a pH-adjusting agent when a buffer is added to the aqueous phase, a pH-adjusting agent may not be added to the aqueous phase. It is understood that a buffer can be added to the aqueous phase or the buffer can be added to the emulsion.
  • the aqueous phase of the emulsion contains a tonicity agent such as sucrose.
  • the tonicity agent is added to an aqueous phase having about 0% to 30%, 0% to 25% or about 20% of the tonicity agent (wt/wt). It was surprisingly found that a composition containing about 20% sucrose wt/wt in the aqueous phase produced an emulsion that was particularly stable as determined by freeze-thaw testing.
  • preferred embodiments include an emulsion in which the aqueous phase comprises a tonicity agent which imparts greater chemical and/or physical stability as compared to an emulsion wherein the aqueous phase contains less than about 10%, 15% or 20% wt/wt tonicity agent or more than about 30%, 40% or 50% wt/wt tonicity agent.
  • the aqueous phase further comprises dexamethasone sodium phosphate (also referred to as "dexamethasone phosphate").
  • Dexamethasone sodium phosphate is a corticosteroid which is freely soluble in water.
  • Daily dosages for dexamethasone sodium phosphate range from about 0.5 mg to 20 mg, more preferably from about 14 mg to 18 mg or 16 mg, depending on the severity of the disease or disorder.
  • an NK-1 receptor antagonist emulsion further comprising dexamethasone may contain dexamethasone sodium phosphate in the aqueous phase.
  • the aqueous phase of an emulsion suitable for intravenous administration may contain about 0.5 mg to 20 mg, 14 mg to 18 mg or about 16 mg dexamethasone sodium phosphate.
  • a solution of dexamethasone sodium phosphate can be mixed into the fine emulsion prior to sterile filtration to prepare an emulsion containing dexamethasone sodium phosphate in the aqueous phase,
  • compositions comprising NK-1 receptor antagonists as disclosed herein are sterile oil-in-water emulsions comprising the aqueous and oil phases described above. Also encompassed by the disclosure are methods for preparing stable emulsions comprising the receptor antagonist which are suitable for intravenous administration and which can be prepared according to the conventional manufacturing procedures using aseptic techniques. [0113] The aqueous phase is combined with the oil phase, under high-speed homogenization to produce a coarse emulsion. Examples 1-6 and 12-19 provide examples of NK-1 receptor antagonist emulsions which are produced using compositions and methods disclosed herein.
  • the combined aqueous and oil phases is homogenized using an IKA Ultra-Turrax T25 dispersing instrument at a speed of 20,000 rpm for 1 min.
  • the speed used in this first homogenization step may vary, for example, from 2000 rpm to 25,000 rpm, or from 15,000 rpm to 22,000 rpm.
  • the time of the homogenization step can also vary, for example, from 0.5 min to 1 hour, or from 1 min to 45 min.
  • This crude emulsion is then homogenized into a fine emulsion by a high-pressure homogenizer, which may be a microfluidizer.
  • the interaction chamber and the cooling coil portions of the microfluidizer are cooled by water, such as by an ice bath.
  • the temperature of the ice bath may be between 0 to 10 °C, or 2 to 6 °C.
  • the temperature of the emulsion coming out of the high-pressure homogenization may be between 0 to 60 °C, 15 °C, to 60 °C, 20 °C to 40 °C, or at about 25 °C.
  • the microfluidizer is first primed with water and then the crude emulsion is introduced. The output from the homogenizer is initially run to waste to remove priming water, and priming water and emulsion mixtures, and then collected in a clean vessel when the stream becomes consistent in appearance.
  • the high-pressure homogenizer cycle may be repeated to sufficiently reduce oil droplet size.
  • the pressure used for the homogenization may vary.
  • the pressures may be between 5000 and 30,000 psi.
  • the number of passes through the microfluidizer may vary in order to achieve the desired droplet size. The number of passes may be from about 2 to 20, 2 to 15, 4 to 15, 4 to 12
  • the pharmaceutical formulation may then be passed through a filter system at room temperature, and/or autoclaved, to achieve sterilization.
  • the filters used to achieve sterilization may be chosen by the skilled artisan and may have a nominal pore size of 0.2 ⁇ .
  • the filter material used may vary.
  • the filter is nylon.
  • the filter is a Posidyne® filter (covalent charge-modified Nylon 6,6 membrane which exhibits a net positively- charged zeta potential in aqueous solutions).
  • Posidyne® filter covalent charge-modified Nylon 6,6 membrane which exhibits a net positively- charged zeta potential in aqueous solutions.
  • a skilled practitioner could combine these materials in a different order and using different processing equipment to achieve the desired end result.
  • the homogenization can be done in repeated cycles to achieve an emulsion in which the oil particle/globule size is less than 2 microns ( ⁇ ) with intermediate cooling of the homogenized product to a temperature less than about 25 °C.
  • the final emulsion comprises an oil portion (oil phase) dispersed in an aqueous portion (aqueous phase).
  • oil phase comprises the NK-1 receptor antagonist, an oil and an emulsifier, examples of which are provided herein.
  • the final emulsion contains about 0.7 wt/wt% of the NK-1 receptor antagonist, but may range from about 0.2 wt/wt% to 1.5 wt/wt%, 0.4 wt/wt% to 1.0 wt/wt%, 0.6 wt/wt% to 0.7 wt/wt%, or 0.7 wt/wt% to 0.8 wt/wt%.
  • the emulsion is prepared which can contain about 130 mg of the NK-1 receptor antagonist, however, preparations may also be prepared according to the present disclosure which contain about 100 mg to 1000 mg, 100 mg to 500 mg, 250 mg to 750 mg or 100 mg to 200 mg NK-1 receptor antagonist.
  • the ratio of oil:NK-l receptor antagonist (wt%:wt%) within the oil phase of the final emulsion is about 13: 1 to 14: 1, but can range from about 11 : 1 to 15: 1, 12: 1 to 14: 1, 13: 1 to 13.5: 1, or 12: 1 to 15: 1.
  • the ratio of oil:NK-l receptor antagonist is about 11 : 1, 11.5: 1, 12: 1, 12.5: 1, 13: 1, 13.5: 1, 14: 1, 14.5: 1 or 15: 1.
  • the ratio of emulsifier to NK-1 receptor antagonist in the final emulsion can be about 20: 1 but may also vary.
  • the ratio of emulsifier:NK-l receptor antagonist (wt%:wt%) within the oil portion ranges from about 15: 1 to 30: 1, 20: 1 to 25: 1, 18: 1 to 22: 1, 19: 1 to 20: 1, or 10: 1 to 30: 1.
  • the emulsifier:NK-l receptor antagonist (wt%:wt%) is about 15: 1, 18: 1, 19: 1, 20: 1, 21 : 1, 22: 1 or 23: 1.
  • the ratio of components within the oil phase of the final emulsion may alternatively be expressed in the ratio of (emulsifier plus oil):NK-l receptor antagonist (wt%:wt%).
  • the ratio of (emulsifier plus oil):NK-l receptor antagonist can be about 33: 1, but the ratios for the present emulsion can range from about 20: 1 to 40: 1, 25: 1 to 35: 1, 30: 1 to 35: 1 or 33: 1 to 37: 1, or may be, for example, about 30: 1, 32: 1, 33: 1, 34: 1, 35: 1, 36: 1, 37: 1, 38: 1 or 40: 1.
  • composition of the present disclosure has a significant advantage in terms of reduced toxicity as compared to injectable formulations which may contain less desirable excipients such as detergents, e.g., Tween-20 or Tween-80.
  • the present formulations take advantage of the ability to solubilize therapeutically effective amounts of a NK-1 receptor antagonist in an oil phase which can then be used to generate an emulsion suitable for injection.
  • described herein are pharmaceutical emulsion compositions containing a NK-1 receptor antagonist and optionally dexamethasone or dexamethasone sodium phosphate, wherein the emulsion does not comprise a detergent.
  • the composition of the present disclosure gives a product suitable for parenteral use because of low particle size.
  • the composition of the present disclosure is easy to use as the product can be diluted with an agent such as an aqueous solution of sucrose, an aqueous solution of maltose or dextrose 5% injection or normal saline to achieve the required concentration for parenteral administration.
  • the composition of the present disclosure also has a prolonged shelf life and hence is suitable for a readily marketable product.
  • the compositions of the disclosure are both chemically and physically stable.
  • a physically stable emulsion of the invention is one which can be stored under appropriate conditions for at least 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 24 or 36 months, without an increase in average droplet size above that allowed as stated in USP ⁇ 729>.
  • the population of large-diameter fat globules should be within the limits stated in USP ⁇ 729>.
  • Droplet size limits defined in USP ⁇ 729> apply throughout the assigned shelf life, which for a commercial pharmaceutical formulation may extend to 2-3 years or longer. All true emulsions are thermodynamically unstable and may over time undergo a range of processes which tend to increase the droplet size. These include direct droplet coalescence, when two droplets collide and form a single new droplet, and aggregation, in which droplets adhere together to form larger masses. Aggregation may in some cases be a precursor of further coalescence into larger droplets. These processes may result in large aggregates rising to the surface of the container, a phenomenon known as 'creaming', and ultimately to free oil being visible on the emulsion surface, known as 'cracking'.
  • Droplet size limits are typified by USP33-NF28 General Chapter ⁇ 729> for Globule Size Distribution in Lipid Injectable Emulsions, hereinafter referred to as USP ⁇ 729>, which defines universal limits for (1) mean droplet size not exceeding 500 nm or 0.5 ⁇ and (2) the population of large-diameter fat globules, expressed as the volume-weighted percentage of fat greater than 5 ⁇ (PFAT5) not exceeding 0.05%, irrespective of the final lipid concentration.
  • PFAT5 volume-weighted percentage of fat greater than 5 ⁇
  • Droplet size measurements such as those defined in USP ⁇ 729> can measure the initial increases in size, and hence are predictive of emulsion physical stability, at early times, long before the formulation shows macroscopic visible changes. Accordingly, the emulsions as described herein are stable compositions having an intensity -weighted mean droplet diameter less than about 500 nm, 400 nm, 300 nm, 200 nm or 100 nm.
  • the oil or particle droplet size, i.e. diameter, according to the present disclosure is measured using a dynamic light scattering (DLS) instrument, such as the Malvern Zetasizer 4000, Malvern Zetasize Nano S90 or preferably the Malvern Zetasizer Nano ZS. Intensity -weighted particles sizes were recorded, since they do not require the knowledge of the refractive index of the particle.
  • DLS dynamic light scattering
  • Malvern Zetasizer instruments there are two fits for determining the intensity -weighted diameter of the oil droplet size. The first is a cumulant fit that is used to determine the Z-average diameter; this fit can additionally give the polydispersity index (PDI).
  • PDI polydispersity index
  • the emulsion preparations as described herein may further comprise a preservative in quantities that preserve the composition.
  • Suitable preservatives used in some of the embodiments of present disclosure include, but are not limited to, disodium edetate, tocopherol, benzalkonium chloride, methyl, ethyl, propyl or butylparaben, benzyl alcohol, phenylethyl alcohol, benzethonium, chlorobutanol, potassium sorbate or combination thereof.
  • compositions of the present disclosure can be used for the prevention or treatment of emesis and provide a non-oral option for patients undergoing highly or moderately emetogenic chemotherapy such as chemotherapy used in cancer patients.
  • the disclosure thus encompasses a method of treatment comprising intravenously administering an emulsion comprising a NK-1 receptor antagonist as described herein to a subject undergoing highly or moderately emetogenic chemotherapy whether the chemotherapy is an initial treatment or repeat courses of the chemotherapy.
  • the pharmaceutical emulsions described herein can be used, for example, in preventing or treating acute and delayed nausea and vomiting associated with the chemotherapy or radiotherapy.
  • Another embodiment relates to the use of the pharmaceutical formulations of the disclosure in the manufacture of a medicament for use preventing or treating emesis in a subject in need thereof.
  • the amount of the NK-1 receptor antagonist and optionally dexamethasone required for use in the methods of the disclosure may vary with the method of administration and condition of the patient, and the degree of therapy required, and will be ultimately at the discretion of the attendant physician or clinician.
  • Example 1 Preparing Aprepitant Emulsions for Intravenous Injection
  • an oil phase was first prepared by combining 750 mg of aprepitant and 15.0 g of egg lecithin (LIPOID E 80) with 12.0 ml of ethanol. This mixture was dissolved by heating and stirring at 60 °C and 200 rpm for 15 min. To the resultant solution was added in 10.0 g of soybean oil. Heating at 60 °C and stirring at 200 rpm was continued for another 15 min.
  • the aqueous phase was prepared by dissolving 5.60 g of sucrose and 0.500 g of sodium oleate in 70.0 ml of water for injection. This mixture was stirred at 300 rpm at room temperature for 30 min.
  • the aqueous phase was then added to the oil phase and subsequently subjected to high-speed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion was then passed 8 times through an ice- cooled high-pressure microfluidizer (Microfluidizer® M-1 10L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • the resultant fine emulsion was sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Coming).
  • Table 1 The details of the emulsion composition are provided in Table 1 below.
  • an oil phase was first prepared by combining 450 mg of aprepitant and 9.00 g of egg lecithin (LIPOID E 80) with 4.0 ml of ethanol. This mixture was dissolved by heating and stirring at 60 °C and 200 rpm for 15 min. To the resultant solution was added 6.00 g of soybean oil. Heating at 60 °C and stirring at 200 rpm was continued for another 15 min.
  • the aqueous phase was prepared by dissolving 3.36 g of sucrose and 0.300 g of sodium oleate in 42.0 ml of water for injection. This mixture was stirred at 300 rpm at room temperature for 30 min.
  • the aqueous phase was then added to the oil phase and subsequently subjected to high-speed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion was then passed 8 times through an ice-cooled high-pressure microfluidizer (Microfluidizer® M-110L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • the resultant fine emulsion was sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Corning).
  • Table 2 The details of the emulsion composition are provided in Table 2 below.
  • the intensity-weighted particle size analyzed using NNLS fit gave a Peak 1 diameter of 127 nm.
  • the intensity -weighted mean particle sized determined using cumulant fit provided a Z-average diameter of 101 nm.
  • the zeta potential was measured to be -47 mV by laser Doppler micro-electrophoresis (Malvern® Zetasizer Nano ZS).
  • the pH of the injectable emulsion was 8.77. This aprepitant-containing emulsion can be injected as is, or diluted for infusion with 5% dextrose or 0.9% saline.
  • Example 3 Preparing Aprepitant Emulsions for Intravenous Injection
  • an oil phase was first prepared by combining 450 mg of aprepitant and 9.00 g of egg lecithin (LIPOID E 80) with 6.0 ml of ethanol. This mixture was dissolved by heating and stirring at 60 °C and 200 rpm for 15 min. To the resultant solution was added in 6.00 g of soybean oil. Heating at 60°C and stirring at 200 rpm was continued for another 15 min.
  • the aqueous phase was prepared by dissolving 15.62 g of sucrose and 0.300 g of sodium oleate in 42.0 ml of water for injection. This mixture was stirred at 300 rpm at room temperature for 30 min.
  • the aqueous phase was then added to the oil phase and subsequently subjected to highspeed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion was then passed 8 times through an ice-cooled high-pressure microfluidizer (Microfluidizer® M-110L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • the resultant fine emulsion was sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Corning).
  • Table 3 The details of the emulsion composition are provided in Table 3 below.
  • Example 4 Preparing an Alternate Aprepitant Emulsion Formulation for Intravenous Injection
  • An aprepitant emulsion was prepared which has less than 10% wt/wt of the phospholipid emulsifier and which was adjusted to a pH of less than 8.0.
  • an oil phase was first prepared by combining 450 mg of aprepitant and 6.67 g of egg lecithin (LIPOID E 80) with 7.2 ml of ethanol. This mixture was dissolved by heating and stirring at 60 °C and 200 rpm. Heating and stirring was carried out until the ethanol was evaporated and a thick residue was observed. To the resultant solution was added in 6.00 g of soybean oil and an appropriate amount of ethanol to obtain a clear oil phase upon heating at 60°C.
  • the aqueous phase was prepared by dissolving 3.36 g of sucrose in 50.5 ml of water for injection at 60°C. The aqueous phase was then added to the oil phase and subsequently subjected to high-speed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion. The pH of this crude emulsion was adjusted to 7.0 and then passed 8 times through an ice-cooled high-pressure microfluidizer (Microfluidizer® M-110L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • the resultant fine emulsion was sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Corning).
  • the details of the emulsion composition are provided in Table 4 below. Within 4 days post preparation at room temperature, crystals were observed in the product by microscopy. Table 4
  • Example 5 Preparing Aprepitant Emulsions for Intravenous Injection
  • An aprepitant emulsion was prepared which contains oleic acid.
  • an oil phase was first prepared by combining 250 mg of aprepitant, 2.50 g of egg lecithin (LIPOID E 80), 15.0 g of soybean oil and 125 mg of oleic acid.
  • Ten ml of ethanol was added to dissolve the mixture at 70 °C. The ethanol was removed by pressure reduction in a 70 °C water bath to yield a clear oil phase.
  • a preheated aqueous phase containing 82.1 ml of water for injection at 70 °C was added to the oil phase and subsequently subjected to high-speed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion was passed 8 times through an ice-cooled high-pressure microfluidizer (Microfluidizer® M-110L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • the resultant fine emulsion was sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Corning).
  • the details of the emulsion composition are provided in Table 5 below. Within 4 days post-preparation at room temperature, crystals were observed in the product by microscopy.
  • Example 6 Preparing Emulsions Containing Aprepitant and Dexamethasone Sodium Phosphate for Intravenous Injection
  • an oil phase was first prepared by combining 773 mg of aprepitant and 15.5 g of egg lecithin (LIPOID E 80) with 10.3 ml of ethanol. This mixture was dissolved by heating and stirring at 60 °C and 200 rpm for 15 min. To the resultant solution was added in 10.3 g of soybean oil. Heating at 60 °C and stirring at 200 rpm was continued for another 15 min.
  • the aqueous phase was prepared by dissolving 5.77 g of sucrose and 0.515 g of sodium oleate in 71.1 ml of water for injection.
  • This mixture was stirred at 300 rpm at room temperature for 30 min.
  • the aqueous phase was then added to the oil phase and subsequently subjected to high-speed homogenization (Ultra- Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion was then passed 8 times through an ice-cooled high-pressure microfluidizer (Microfluidizer® M-1 10L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • Dexamethasone sodium phosphate (93.5 mg) dissolved in 1 ml of water for injection was mixed into the fine emulsion.
  • the pH of the injectable emulsion was 8.92.
  • This aprepitant and dexamethasone sodium phosphate containing emulsion can be injected as is, or diluted for infusion with 5% dextrose or 0.9% saline.
  • Example 7 Stability of the Aprepitant Emulsion at Room Temperature and 5 °C
  • Stability of the aprepitant emulsions prepared as described in Examples 1, 2 3 and 6 was measured by incubating each emulsion preparation at room temperature (about 25 °C) or at 5 °C. Mean particle size and percentage of fat globules above 5 ⁇ were measured using DLS and light obscuration respectively to determine if they satisfy USP ⁇ 729>. The emulsions were also inspected by microscopy for aprepitant crystals. Example 1 was stable at room temperature for 2 months, that is, the mean particle size and percentage of fat globules above 5 ⁇ satisfied USP ⁇ 729>. Additionally, no aprepitant crystals were visible by microscopy.
  • Examples 1 and 6 After 2 months storage at room temperature, creaming was observed in Examples 1 and 6. This corresponded with the observation of aprepitant crystals. Examples 2 and 3 were stable at room temperature for 3 and 2 months respectively. After these time points, aprepitant crystals were observed in these formulations. Storage at 5 °C resulted in longer emulsion stability for Examples 1, 2, 3 and 6. Table 7 shows the characterizations of Examples 1, 2, 3 and 6 and their respective stabilities at room temperature and at 5 °C.
  • Example 8 Stability of the Aprepitant Emulsion to Freeze-Thaw Cycle
  • FIG. 1 shows microscope images, at 10X, of emulsions after the freeze-thaw cycle (Examples 1, 2, 3 and 6 are shown as FIG. 1 A, B, C, and D, respectively).
  • Emulsions prepared as described in examples 1, 2 and 6 showed visible particles after exposure to freezing. Only Example 3 was stable after freezing. As FIG. 1C shows, no visible particles were observed for the formulation of Example 3. This enhanced stability was conferred by the presence of a large concentration of sucrose (20 w/w% in Example 3 compared to 5 w/wt% in Examples 1, 2 and 6).
  • Example 1 The pharmacokinetics of an aprepitant emulsion prepared according to Example 1 was determined. Two groups of six male Sprague-Dawley rats each were injected intravenously with, respectively, fosaprepitant in solution or aprepitant emulsion prepared according to Example 1. All drugs were administered at an effective concentration equivalent to 14 mg/kg aprepitant. Blood from all rats was collected at the appropriate time intervals and processed to plasma by centrifugation. Plasma samples were analyzed by LC-MS/MS for aprepitant and fosaprepitant, as appropriate. A plasma concentration versus time curve of aprepitant for the emulsion described in Example 1 and for fosaprepitant is presented in FIG.
  • Example 10 Pharmacokinetics of an Aprepitant and Dexamethasone Emulsion
  • a dose was administered at an effective drug concentration equivalent to 2 mg/kg aprepitant.
  • a dose was administered at an effective drug concentration equivalent to 0.24 mg/kg dexamethasone sodium phosphate.
  • Blood from all rats was collected at the appropriate time intervals and processed to plasma by centrifugation. Plasma samples were analyzed by LC-MS/MS for dexamethasone, aprepitant, and fosaprepitant, as appropriate.
  • FIGS. 3 and 4 present the plasma concentration versus time curve of aprepitant and dexamethasone, respectively.
  • FIG. 3 compares the aprepitant plasma concentration versus time curve resulting from injection of the emulsion described in Example 6 (FIG. 3, ⁇ ) vs. injection of a solution of fosaprepitant (FIG. 3, A ).
  • FIG. 4 compares the dexamethasone plasma concentration versus time curve resulting from injection of a dexamethasone sodium phosphate solution (FIG. 4, ⁇ ) vs. injection of the emulsion described in Example 6. The curves indicate that the aprepitant in the emulsion is released approximately simultaneously with the dexamethasone sodium phosphate. The presence of dexamethasone sodium phosphate in the emulsion does not affect the pharmacokinetics of aprepitant.
  • Example 1 1 Preparing Aprepitant Emulsions for Intravenous Injection
  • an oil phase is first prepared by combining 750 mg of aprepitant, 15.0 g of egg lecithin (LIPOID E 80), 10.0 g of soybean oil and 3.75 ml of ethanol. This mixture is dissolved by heating and stirring at 70 °C and 200 rpm for 30 min.
  • the aqueous phase is prepared by dissolving 2.17 g of sucrose and 0.500 g of sodium oleate in a mixture of 4.1 ml of 1M Tris buffer (pH 8.4) and 65.9 ml of water for injection. This mixture is stirred at 300 rpm at room temperature for 30 min.
  • the aqueous phase is then added to the oil phase and subsequently subjected to high-speed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion is then passed 8 times through an ice-cooled high-pressure microfiuidizer (Microfiuidizer® M-1 10L, F 12Y interaction chamber) at a pressure of 18,000 psi.
  • the resultant fine emulsion is sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Corning).
  • Dynamic light scattering is used to determine the intensity-weighted particle size using NNLS fit to give the Peak 1 diameter, the intensity-weighted mean particle sized is determined using cumulant fit to provide the Z-average diameter.
  • the zeta potential is measured by laser Doppler micro-electrophoresis (Malvern® Zetasizer Nano ZS). This aprepitant-containing emulsion can be injected as is, or diluted for infusion with 5% dextrose or 0.9% saline.
  • an oil phase was first prepared by combining 1.080 g of rolapitant and 21.6 g of egg lecithin (LIPOID E 80) with 14.4 g of soybean oil and 5.40 ml of ethanol in a glass jar. This mixture was allowed to incubate at room temperature for 30 min followed by heating and stirring at 70°C and 200 rpm for another 30 min.
  • the aqueous phase was prepared by dissolving 8.06 g of sucrose and 0.720 g of sodium oleate in 100.8 ml of water for injection by heating and stirring at 35°C and 300 rpm for 15 min.
  • the aqueous phase was then added to the oil phase and subsequently subjected to high-speed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion was passed 8 times through a high-pressure microfiuidizer (Microfiuidizer® M-110P, F12Y interaction chamber) at a pressure of 20,000 psi.
  • the outlet fine emulsion temperature was kept at approximately 25°C using cooling water.
  • the resultant fine emulsion was sterilized by passing through a 0.2 ⁇ nylon filter (Nalgene). Details of the emulsion composition are provided in Table 8 below.
  • Example 13 Preparing Netupitant Emulsions for Intravenous Injection
  • an oil phase is first prepared by combining about 750 mg of netupitant and 15.0 g of egg lecithin (LIPOID E 80) with 12.0 ml of ethanol. This mixture is dissolved by heating and stirring at 60 °C and 200 rpm for 15 min. To the resultant solution is added in 10.0 g of soybean oil. Heating at 60 °C and stirring at 200 rpm is continued for another 15 min.
  • the aqueous phase is prepared by dissolving 5.60 g of sucrose and 0.500 g of sodium oleate in 70.0 ml of water for injection. This mixture is stirred at 300 rpm at room temperature for 30 min.
  • the aqueous phase is then added to the oil phase and subsequently subjected to high-speed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion is then passed 8 times through an ice-cooled high-pressure microfiuidizer (Microfluidizer® M-110L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • the resultant fine emulsion is sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Coming).
  • Table 10 The details of the emulsion composition are provided in Table 10 below.
  • the intensity-weighted particle size is analyzed using non-negative least squares (NNLS) fit to obtain a Peak 1 diameter of the particle.
  • the intensity-weighted mean particle size is also determined using cumulant fit and provides a Z-average diameter.
  • the zeta potential is measured to be -43 mV by laser Doppler micro-electrophoresis (Malvern® Zetasizer Nano ZS).
  • the pH of the injectable emulsion is also measured and is preferably about pH 7.8 to 8.8.
  • This NK-1 receptor antagonist- containing emulsion can be injected as is, or diluted for infusion with 5% dextrose or 0.9% saline.
  • an oil phase is first prepared by combining about 450 mg of netupitant and 9.00 g of egg lecithin (LIPOID E 80) with 4.0 ml of ethanol. This mixture is dissolved by heating and stirring at 60 °C and 200 rpm for 15 min. To the resultant solution is added 6.00 g of soybean oil. Heating at 60 °C and stirring at 200 rpm is continued for about another 15 min.
  • the aqueous phase is prepared by dissolving 3.36 g of sucrose and 0.300 g of sodium oleate in 42.0 ml of water for injection. This mixture is stirred at 300 rpm at room temperature for 30 min.
  • the aqueous phase is then added to the oil phase and subsequently subjected to high-speed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion is then passed 8 times through an ice-cooled high-pressure microfluidizer (Microfluidizer® M-110L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • the resultant fine emulsion is sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Corning).
  • Table 11 The details of the emulsion composition are provided in Table 11 below.
  • the intensity -weighted particle size is analyzed using NNLS fit to give a Peak 1 diameter.
  • the intensity -weighted mean particle size is determined using cumulant fit provides a Z-average diameter.
  • the zeta potential is measured by laser Doppler micro-electrophoresis (Malvern® Zetasizer Nano ZS).
  • the pH of the injectable emulsion is also measured and is preferably about pH 7.8 to 8.8. This netupitant-containing emulsion can be injected as is, or diluted for infusion with 5% dextrose or 0.9% saline.
  • an oil phase is first prepared by combining 450 mg of netupitant and 9.00 g of egg lecithin (LIPOID E 80) with 6.0 ml of ethanol. This mixture is dissolved by heating and stirring at 60 °C and 200 rpm for 15 min. To the resultant solution is added in 6.00 g of soybean oil. Heating at 60°C and stirring at 200 rpm is continued for another 15 min.
  • the aqueous phase is prepared by dissolving 15.62 g of sucrose and 0.300 g of sodium oleate in 42.0 ml of water for injection. This mixture is stirred at 300 rpm at room temperature for 30 min.
  • the aqueous phase is then added to the oil phase and subsequently subjected to high-speed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion is then passed 8 times through an ice-cooled high-pressure microfluidizer (Microfluidizer® M-110L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • the resultant fine emulsion is sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Corning).
  • Table 12 The details of the emulsion composition are provided in Table 12 below.
  • the intensity -weighted particle size is analyzed using NNLS fit gave a Peak 1 diameter.
  • the intensity-weighted mean particle size is determined using cumulant fit provided a Z-average diameter.
  • the zeta potential is measured by laser Doppler micro-electrophoresis (Malvern® Zetasizer Nano ZS).
  • the pH of the injectable emulsion is also measured and is preferably about pH 7.8 to 8.8. This netupitant-containing emulsion is to be diluted with water for injection by 4-fold prior to injection. Table 12
  • Example 16 Alternate Netupitant Emulsion Formulations for Intravenous Injection
  • a netupitant emulsion is prepared which has less than 10% wt/wt of the phospholipid emulsifier and which is adjusted to a pH of less than 8.0.
  • an oil phase is first prepared by combining 450 mg of netupitant and 6.67 g of egg lecithin (LIPOID E 80) with 7.2 ml of ethanol. This mixture is dissolved by heating and stirring at 60 °C and 200 rpm. Heating and stirring is carried out until the ethanol is evaporated and a thick residue is observed.
  • To the resultant solution is added in 6.00 g of soybean oil and an appropriate amount of ethanol to obtain a clear oil phase upon heating at 60°C.
  • the aqueous phase is prepared by dissolving 3.36 g of sucrose in 50.5 ml of water for injection at 60°C.
  • the aqueous phase is then added to the oil phase and subsequently subjected to high-speed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • the pH of this crude emulsion is adjusted to 7.0 and then passed 8 times through an ice-cooled high-pressure microfluidizer (Microfluidizer® M-110L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • the resultant fine emulsion is sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Corning).
  • the details of the emulsion composition are provided in Table 13 below.
  • the emulsion product is analyzed for the presence of crystals by microscopy. Table 13
  • Example 17 Alternate Netupitant Emulsion Formulations for Intravenous Injection
  • a netupitant emulsion is prepared which contains oleic acid.
  • an oil phase is first prepared by combining 250 mg of netupitant, 2.50 g of egg lecithin (LIPOID E 80), 15.0 g of soybean oil and 125 mg of oleic acid.
  • Ten ml of ethanol is added to dissolve the mixture at 70 °C. The ethanol is removed by pressure reduction in a 70 °C water bath to yield a clear oil phase.
  • a preheated aqueous phase containing 82.1 ml of water for injection at 70 °C is added to the oil phase and subsequently subjected to high-speed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion is passed 8 times through an ice-cooled high-pressure microfluidizer (Microfluidizer® M-110L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • the resultant fine emulsion is sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Coming).
  • the details of the emulsion composition are provided in Table 14 below.
  • Example 18 Preparing Emulsions Containing Netupitant and Dexamethasone Sodium Phosphate for Intravenous Injection
  • an oil phase are first prepared by combining 773 mg of netupitant and 15.5 g of egg lecithin (LIPOID E 80) with 10.3 ml of ethanol. This mixture is dissolved by heating and stirring at 60 °C and 200 rpm for 15 min. To the resultant solution is added in 10.3 g of soybean oil. Heating at 60 °C and stirring at 200 rpm is continued for another 15 min.
  • the aqueous phase is prepared by dissolving 5.77 g of sucrose and 0.515 g of sodium oleate in 71.1 ml of water for injection.
  • This mixture is stirred at 300 rpm at room temperature for 30 min.
  • the aqueous phase is then added to the oil phase and subsequently subjected to high-speed homogenization (Ultra-Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion is then passed 8 times through an ice-cooled high-pressure microfiuidizer (Microfluidizer® M-110L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • Dexamethasone sodium phosphate (93.5 mg) dissolved in 1 ml of water for injection is mixed into the fine emulsion.
  • This resultant fine emulsion containing both netupitant and dexamethasone sodium phosphate is sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Corning).
  • the details of the emulsion composition are provided in Table 6 below.
  • dynamic light scattering Malvern® Zetasizer Nano ZS
  • the intensity -weighted particle size is analyzed using N LS fit to determine a Peak 1 diameter.
  • the intensity -weighted mean particle size is determined using cumulant fit to determine a Z-average diameter.
  • the zeta potential is measured to be -43 mV by laser Doppler micro-electrophoresis (Malvem® Zetasizer Nano ZS).
  • the preferred pH of the injectable emulsion is between about 8.5 and 9.5.
  • This netupitant and dexamethasone sodium phosphate containing emulsion can be injected as is, or diluted for infusion with 5% dextrose or 0.9% saline.
  • Example 19 Preparing NK-1 Receptor Antagonist Emulsions for Intravenous Injection
  • an oil phase is first prepared by combining 750 mg of aprepitant, 15.0 g of egg lecithin (LIPOID E 80), 10.0 g of soybean oil and 3.75 ml of ethanol. This mixture is dissolved by heating and stirring at 70 °C and 200 rpm for 30 min.
  • the aqueous phase is prepared by dissolving 2.17 g of sucrose and 0.500 g of sodium oleate in a mixture of 4.1 ml of 1M Tris buffer (pH 8.4) and 65.9 ml of water for injection. This mixture is stirred at 300 rpm at room temperature for 30 min.
  • the aqueous phase is then added to the oil phase and subsequently subjected to high-speed homogenization (Ultra- Turrax® IKA T25) at a speed of 20,000 rpm for 1 min to produce the crude emulsion.
  • This crude emulsion is then passed 8 times through an ice-cooled high-pressure microfluidizer (Microfluidizer® M-110L, F12Y interaction chamber) at a pressure of 18,000 psi.
  • the resultant fine emulsion is sterilized by passing it through a 0.2 ⁇ nylon syringe filter (Coming).
  • Dynamic light scattering is used to determine the intensity-weighted particle size using N LS fit to give the Peak 1 diameter, the intensity -weighted mean particle sized is determined using cumulant fit to provide the Z-average diameter.
  • the zeta potential is measured by laser Doppler micro-electrophoresis (Malvern® Zetasizer Nano ZS). This aprepitant-containing emulsion can be injected as is, or diluted for infusion with 5% dextrose or 0.9% saline.
  • Example 20 Stability of the Rolapitant Emulsion at Room Temperature and 5 °C
  • Stability of the rolapitant emulsion prepared as described in Example 12 was measured by incubating the emulsion preparation at room temperature (about 25 °C) or at 5 °C. Mean particle size and percentage of fat globules above 5 ⁇ were measured using DLS and light obscuration respectively and demonstrated to satisfy USP ⁇ 729> after 2 months of storage. The emulsions were also inspected by microscopy for rolapitant crystals and visually for the presence of emulsion creaming. The absence of crystals or emulsion creaming further indicated product stability.
  • Example 21 Stability of the Netupitant Emulsion at Room Temperature and 5 °C
  • Stability of the netupitant emulsions prepared as described in Examples 13-17 can be measured by incubating each emulsion preparation at room temperature (about 25 °C) or at 5 °C. Mean particle size and percentage of fat globules above 5 ⁇ are measured using DLS and light obscuration respectively to determine if they satisfy USP ⁇ 729>. The emulsions are also inspected by microscopy for netupitant crystals and/or visually for the presence of emulsion creaming. The absence of crystals or emulsion creaming indicates product stability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16708789.9A 2016-02-01 2016-02-01 Emulsion comprising an nk-1 receptor antagonist Withdrawn EP3411013A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/015992 WO2017135923A1 (en) 2016-02-01 2016-02-01 Emulsion comprising an nk-1 receptor antagonist

Publications (1)

Publication Number Publication Date
EP3411013A1 true EP3411013A1 (en) 2018-12-12

Family

ID=55487067

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16708789.9A Withdrawn EP3411013A1 (en) 2016-02-01 2016-02-01 Emulsion comprising an nk-1 receptor antagonist

Country Status (7)

Country Link
EP (1) EP3411013A1 (ja)
JP (1) JP6829257B2 (ja)
KR (1) KR20180118136A (ja)
CN (1) CN108883058A (ja)
AU (1) AU2016391046A1 (ja)
CA (1) CA3013288A1 (ja)
WO (1) WO2017135923A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019214872A1 (en) * 2018-01-30 2020-08-06 Heron Therapeutics, Inc. Method of administering emulsion formulations of an NK-1 receptor antagonist
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
CN108703950B (zh) * 2018-08-27 2021-04-20 辅必成（上海）医药科技有限公司 一种罗拉吡坦的乳剂注射液
CN109453115A (zh) * 2018-12-25 2019-03-12 广州白云山汉方现代药业有限公司 一种罗拉匹坦静脉注射乳剂及其制备方法和应用
CN111388419A (zh) * 2019-01-03 2020-07-10 齐鲁制药有限公司 阿瑞匹坦乳剂
CN110772482A (zh) * 2019-12-02 2020-02-11 广州白云山汉方现代药业有限公司 一种高比例乳化剂的乳剂及其制备方法
JP2023169445A (ja) * 2020-10-08 2023-11-30 丸石製薬株式会社 ホスアプレピタント注射剤希釈液による細胞毒性抑制剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2609640T3 (es) * 2009-08-14 2017-04-21 Opko Health, Inc Formulaciones intravenosas de rolapitant
CN102379845A (zh) * 2011-11-03 2012-03-21 南京优科生物医药有限公司 一种注射用阿瑞匹坦微乳剂及其制备方法
CA2874700A1 (en) * 2012-05-24 2013-11-28 Innopharma, Inc. Aprepitant injectable formulations
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
RS60599B1 (sr) * 2012-07-06 2020-08-31 Pharmathen Sa Stabilna injektibilna farmaceutska kompozicija antagonista neurokinin-1-receptora i postupak za njeno dobijanje
KR20160023692A (ko) * 2013-06-24 2016-03-03 타이거캣 파마, 인크. 소양증에서의 nk-1 수용체 길항제 세를로피탄트의 용도
US9808465B2 (en) * 2014-09-19 2017-11-07 Heron Therapeutics, Inc. Emulsion formulations of aprepitant

Also Published As

Publication number Publication date
CA3013288A1 (en) 2017-08-10
AU2016391046A1 (en) 2018-08-16
JP6829257B2 (ja) 2021-02-10
JP2019507131A (ja) 2019-03-14
CN108883058A (zh) 2018-11-23
KR20180118136A (ko) 2018-10-30
WO2017135923A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
US10953018B2 (en) Emulsion formulations of aprepitant
US11744800B2 (en) Methods of use of emulsion formulations of an NK-1 receptor antagonist
EP3411013A1 (en) Emulsion comprising an nk-1 receptor antagonist
US20190231688A1 (en) Method of administering emulsion formulations of an nk-1 receptor antagonist
JP2020109115A (ja) Ｎｋ−１受容体アンタゴニストを含むエマルジョン
JP2021088583A (ja) Ｎｋ−１受容体アンタゴニストを含むエマルジョン

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180815

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40001723

Country of ref document: HK

17Q First examination report despatched

Effective date: 20200218

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220901